<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; MTX</title>
	<atom:link href="http://www.stockbloghub.com/tag/mtx/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(REGN) Regeneron Pharmaceuticals Gets Mixed Data for REGN88</title>
		<link>http://www.stockbloghub.com/2011/07/14/regn-regeneron-pharmaceuticals-gets-mixed-data-for-regn88/79111</link>
		<comments>http://www.stockbloghub.com/2011/07/14/regn-regeneron-pharmaceuticals-gets-mixed-data-for-regn88/79111#comments</comments>
		<pubDate>Thu, 14 Jul 2011 21:30:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Minerals Technologies Inc.]]></category>
		<category><![CDATA[MTX]]></category>
		<category><![CDATA[RA]]></category>
		<category><![CDATA[Railamerica Inc]]></category>
		<category><![CDATA[Regeneron Pharmaceuticals Inc]]></category>
		<category><![CDATA[REGN]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=79111</guid>
		<description><![CDATA[Regeneron Pharmaceuticals, Inc. (REGN) and partner Sanofi Aventis (SNY) recently announced data from two mid-stage studies of their pipeline candidate sarilumab (REGN88/SAR153191). While one study (MOBILITY) evaluated patients with rheumatoid arthritis (RA) the other (ALIGN) evaluated ankylosing spondylitis (AS) patients. Sarilumab is an antibody targeting the interleukin-6 receptor (IL-6R). The data from the RA trial was positive while the AS trial data was not too encouraging. The MOBILITY (n=306) trial showed that sarilumab in combination with methotrexate (MTX), the standard of care for RA, led to significant improvement in signs and symptoms of moderate-to-severe RA patients versus patients treated with MTX plus placebo. The trial compared 5 doses of sarilumab plus MTX to placebo plus MTX. 49% of patients receiving the lowest dose met the primary endpoint of at least ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/14/regn-regeneron-pharmaceuticals-gets-mixed-data-for-regn88/79111/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen&#8217;s Rheumatoid Arthritis Candidate Effective</title>
		<link>http://www.stockbloghub.com/2009/12/14/biib-biogens-rheumatoid-arthritis-candidate-effective/22761</link>
		<comments>http://www.stockbloghub.com/2009/12/14/biib-biogens-rheumatoid-arthritis-candidate-effective/22761#comments</comments>
		<pubDate>Tue, 15 Dec 2009 01:28:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[Minerals Technologies Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MTX]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22761</guid>
		<description><![CDATA[Biogen Idec (BIIB) and Genentech Inc., a wholly owned member of the Roche Group (RHHBY), recently reported positive phase III results on their rheumatoid arthritis (RA) candidate, ocrelizumab. Results from the study (STAGE) showed that the humanized anti-CD20 monoclonal antibody, when given in combination with methotrexate (MTX), met its primary endpoint of improving signs and symptoms in RA patients who were not getting an adequate response to MTX at either 24 or 48 weeks. While these results were encouraging, there could be some concern regarding the safety profile of the candidate as the companies reported a higher percentage of serious infections in the pooled ocrelizumab groups when compared to the placebo group. Safety analyses from the study are ongoing and will be presented at an upcoming medical meeting. The international, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/14/biib-biogens-rheumatoid-arthritis-candidate-effective/22761/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

